Introduction {#sec1-1}
============

*Amlapitta* is a very common disease in the society and is an abnormal pathological condition of *Pitta*. *Drava Guna* plays an important role in the pathogenesis of *Amlapitta*.\[[@ref1]\] On the basis of predominant *Rasa* and *Gunatmaka* diet consumed by the patient, one can visualize two types of *Amlapitta* (*Vikalpa Samprapti*) and thus can plan the therapeutic intervention \[[Figure 1](#F1){ref-type="fig"}\]. If *Nidanas* (diet) are *Amla--Lavana--Drava--Snigdha--Ushna* dominant in nature, then *Drava* property of *Pitta* increases, and if *Nidanas* are *Katu*--*Ushna*--*Ruksha* dominant in nature, *Ushna* and *Ruksha* properties of *Pitta* get increased.\[[@ref2]\]

![Pathogenesis of *Amlapitta*](Ayu-32-512-g001){#F1}

The present study was carried out to evaluate clinically *Ruksha* and *Ushna* drug, i.e. *Bhringaraja*, in countering the *Drava Bahula Amlapitta*, thereby suggesting a fundamental approach based line of treatment for *Amlapitta*.

Aims and objectives {#sec2-1}
-------------------

This study was carried out with the following aims and objectives:

To study the applied concept of *Drava Guna* particularly of *Pitta* in *Amlapitta* patients.Evaluation of the efficacy of the selected drug *Bhringaraja* on *Drava Guna Vriddhi* of *Pitta* in comparison to placebo.

Materials and Methods {#sec1-2}
=====================

Criteria of selection of patients {#sec2-2}
---------------------------------

For the clinical study, the patients having the symptoms of *Amlapitta* (with *Drava Guna* dominant symptoms.\[[@ref3]\])Age: 20--60 years.

Patients satisfying the above criteria were selected from the OPD/IPD of Department of Basic Principles, I.P.G.T. and R.A., G.A.U., Jamnagar.

Criteria of exclusion of patients {#sec2-3}
---------------------------------

Patients below 20 years and above 60 years of age.Patients having the symptoms of *Amlapitta* (with *Tyaktadravtva* dominant symptoms\[[@ref3]\]).Patients suffering from complications of *Amlapitta* like gastritis, duodenal ulcer, etc. and also having any endocrine disorder or chronic complicated disease.

Grouping {#sec2-4}
--------

Patients were divided into two groups.

Group A - Treatment groupGroup B - Placebo group

Drug and posology {#sec2-5}
-----------------

The test drug and placebo used in this study were mentioned in [Table 1](#T1){ref-type="table"} with their details.

###### 

Drug, dose, duration

![](Ayu-32-512-g002)

Investigations {#sec2-6}
--------------

Laboratory investigations were carried out before and after treatment to rule out any other pathological conditions as well as to record any specific change brought about by the treatment.

Routine hematological examinations: Total leukocyte count, differential count, hemoglobin percent, packed cell volume and erythrocyte sedimentation rate before and after treatment.Biochemical examination: Serum total proteins and A/G ratio, Blood urea level, serum creatinine, serum uric acid, serum alkaline phosphatase, total lipid profile and fasting blood glucose level before and after treatment.

Study design {#sec2-7}
------------

Placebo-controlled randomized clinical trial was done. Informed written consent was taken from the patients before including them in the trial. An elaborative case taking proforma was specially designed for the purpose of incorporating the disease and *Drava Guna* concept.

*Pathyapathya* (wholesome--unwholesome diet): Patients were advised to take *Pathyahara* and to correct their dietary habits and avoid *Apathyahara* as per the classical guidelines.

Assessment of therapy {#sec2-8}
---------------------

Relief in signs and symptoms of *Amlapitta* was assessed by B.T. and A.T. gradation of clinical features, on the basis of scoring pattern.

Criteria for overall assessment of therapy {#sec2-9}
------------------------------------------

The overall assessment based on relief from the symptoms is shown in [Table 2](#T2){ref-type="table"}.

###### 

Criteria for overall assessment of therapy

![](Ayu-32-512-g003)

Statistical analysis {#sec2-10}
--------------------

The information gathered on the basis of observations was subjected to statistical analysis. Chi-square test and Student\'s paired "*t*" test were carried out for all subjective parameter (symptoms). Student\'s paired "t" test was applied for the objective parameters like hematological and biochemical investigations. The results were interpreted at *P*\<0.05, *P*\<0.01 and *P*\<0.001 significance levels. Total effect of therapy was calculated with the help of Chi-square test.

Observations, Results and Discussion {#sec1-3}
====================================

In the present study, 42 patients of *Amlapitta* \[[Table 3](#T3){ref-type="table"}\] were evaluated. It was found that 42.86% patients were in the age group of 31--40 years \[[Table 4](#T4){ref-type="table"}\], which is *Pitta Dosha* dominance stage of life. This finding correlates with the findings of Iyer Shividya, Prof. R. R. Dwivedi *et al*. (2003) and Santosh Mane, Prof. R. R. Dwivedi *et al*. (2008). At this particular age, strenuous work, traveling, dietetic incompatibilities like *Vishamashana*, ignorance about *Dinacarya*, etc. are the other factors that set a solid foundation for *Pitta* disorders due to vitiation of *Agni*. Maximum (i.e. 69.04%) patients were taking *Snigdha, Ushna, Guru, Drava* diet like oily substance, spicy food which contains Snigdha as well as *Ushna Guna* \[[Table 5](#T5){ref-type="table"}\]. The symptoms exaggerated in 76.12% patients in relation to oily, spicy diet \[[Table 6](#T6){ref-type="table"}\]. These observations of the two tables indicate that *Snigdha--Ushna Gunatmaka*diet provokes the *Drava Bahula Amlapitta* which is in accordance with *Madhukosha* commentary view that *Snigdha* and *Ushna* are *Hetu* for *Pitta Drava Vriddhi*.

###### 

Status of the registered patients of *Amlapitta*

![](Ayu-32-512-g004)

###### 

Age wise distribution of the 42 patients
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###### 

*Gunatmaka* dominancy in diet of the 42 patients
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###### 

*Anupashaya* in relation to oily, spicy diet in 42 patients of *Amlapitta*

![](Ayu-32-512-g007)

Maximum patients (80.95%) were habituated with improper diet styles like *Samashana, Vishamashana and Viruddhashana* \[[Table 7](#T7){ref-type="table"}\]. From this point of view, it can be said that for the manifestation of disease *Amlapitta*, all the above factors may be responsible collectively as well as individually. As per *Acharya Sushruta*, these are the most important factors in creating the *Agnimandya*. However, the role of these factors in increasing *Pitta Dravata* is still not clear. It can be inferred that *Samashana, Vishamashana* and *Viruddhashana* which includes *Snigdha* and *Ushna Gunatmaka* diet may be the reason for increase in *Pitta Dravata*.

###### 

Faulty dietary habits like *Samashana, Vishamashana, Viruddhashana*

![](Ayu-32-512-g008)

On examining the *Shareera Prakrti*, it was observed that maximum (i.e. 35.72%) patients prone to this disease were of *Kapha--Pittaja* and *Kapha--Vata Prakriti*. This shows the tendency of *Kapha Pitta* predominance leading to *Dushti* of *Annavahasrotas* and ultimately producing its symptoms earlier than others \[[Table 8](#T8){ref-type="table"}\]. In *Amlapitta*, *Pitta* is the leading vitiated *Dosha* and *Kapha* is next to *Pitta*. *Kapha* and *Pitta* both have the *Drava Guna*.\[[@ref4]\] Hence, *Pitta* and *Kapha Prakriti* persons are more prone to the disease, *Amlapitta*, as *Drava Guna* of *Pitta* increases in *Amlapitta*.

###### 

*Deha Prakriti* wise distribution of the 42 patients

![](Ayu-32-512-g009)

In this study 88.09% patients were having *Avara Jarana Shakti* \[[Table 9](#T9){ref-type="table"}\]. *Pachaka Pitta* is responsible for digestion. In normal condition, *Pachaka Pitta* is devoid (i.e. a smaller amount) of *Drava Guna*. If *Drava Guna* of *Pachaka Pitta* increases, then it decreases *Ushna Guna* of *Pachaka Pitta* which is the most essential *Guna* for digestion. In *Amlapitta*, due to increase in *Drava Guna* and decrease in *Ushna Guna* of *Pitta, Avara Jarana Shakti* was observed. This is in accordance with the classical view that if *Drava Guna* of *Pitta* increases, then it hampers digestion by creating *Agnimandyata*.\[[@ref5]\]

###### 

*Jarana Shakti* wise distribution of the 42 patients
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Maximum patients (i.e. 57.14%) had been suffering from *Amlapitta* since more than a month \[[Table 10](#T10){ref-type="table"}\]. This indicates *Chirakari Swabhava* of *Amlapitta*. 83.33% and 9.05% of the patients were taking *Guru Bhojana* and *Viruddhahara*, respectively, while 38.10% of the patients were taking *Atisnigdhahara* \[[Table 11](#T11){ref-type="table"}\]. This % of *Aharaja Nidanas* \[[Table 11](#T11){ref-type="table"}\] directly indicates their role in *Amlapitta*. *Annavaha* and *Rasavaha Srotas* involvement was seen in all of the patients (i.e. 100%) \[[Table 12](#T12){ref-type="table"}\]. This observation supports the classical view of *Kashyapa* which indicate *Rasa Dhatu* as the main *Dushya* in *Amlapitta*.\[[@ref6]\]

###### 

Distribution of 42 patients according to the duration of the disease
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###### 

*Nidanas* (etiological factors) observed in 42 patients of *Amlapitta*
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###### 

Involvement of *Srotas* in 42 patients of *Amlapitta*

![](Ayu-32-512-g013)

Percentage of improvement {#sec2-11}
-------------------------

In Group A (*Bhringaraja* treated), 100% relief was observed in *Chhardi* symptom. Next to *Chhardi*, maximum 85.71% relief was observed in *Kandu/Kotha*, followed by 83.33% in *Angasada* and 80.56% in *Amlodgara*. *Utklesha* was reduced by 79.31%, while *Klama* and *Avipaka* improved by 78.26% and 76.92%, respectively. 70.97% relief in *Guru Koshthata* and 66.67% in *Aruchi* were observed. Placebo (Group B) drug showed maximum 52.94% improvement in *Amlodgara* and 50% improvement in *Chhardi*. It also showed improvement in *Utklesha* by 42.11% \[[Figure 2](#F2){ref-type="fig"}\].

![Percentage wise improvement in Groups A and B](Ayu-32-512-g014){#F2}

Use of placebo control excludes the psychological and environmental factors affecting the treatment efficacy. Hence, results obtained in Group A are due to the drug efficacy and not due to the effect of psychological and environmental factors.

Results of student\'s paired "*t*" test {#sec2-12}
---------------------------------------

Statistically highly significant result (*P*\<0.01) was obtained in symptoms like *Utklesha, Amlodgara, Avipaka, Guru Koshthata, Aruchi, Angasada, Klama, Kandu* under Group A. Significant result (*P*\<0.05) was obtained in Gaurava symptom, while nonsignificant result was obtained in *Vid Bheda* in Group A \[[Table 13](#T13){ref-type="table"}\]. Statistically nonsignificant result was obtained in symptoms like *Avipaka, Gaurava, Guru Koshthata, Aruchi, Angasada, Klama, Vid Bheda* in Group B, while statistically significant results (*P*\<0.05) were observed in *Utklesha, Amlodgara* symptoms \[[Table 14](#T14){ref-type="table"}\]. This may be due to *Nidana Parivarjana* and *Pathya* followed by patients.

###### 

Effect of *Bhringaraja* on symptoms of *Amlapitta* in Group A (paired "*t*" test applied to symptoms)
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###### 

Effect of placebo (rice powder tablet) on symptoms of *Amlapitta* in Group B (paired "*t*" test applied to symptoms)
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Result of Chi-square test on individual symptoms {#sec2-13}
------------------------------------------------

This illustrates that test drug *Bhringaraja* is efficacious insignificantly in improving the above individual symptoms \[[Table 15](#T15){ref-type="table"}\]. Small sample size and variation of symptoms, i.e. all the symptoms not being present in each patient, may be the reason behind the insignificant results obtained with Chi-square test.

###### 

Results obtained on applying Chi-square test on the symptoms of *Amlapitta*
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Result of paired "*t*" test applied to hematological data and biochemical parameters of Group A {#sec2-14}
-----------------------------------------------------------------------------------------------

It is evident that the *Bhringaraja* treated group showed statistically significant increase (paired "*t*" test) in four parameters: Hb (gm%) (*P*\<0.001), total red blood cell count (TRBC; ×10^12^/l), packed cell volume (PCV; %), and serum glutamate oxaloacetate transaminase (SGOT) \[[Table 16](#T16){ref-type="table"}\].

###### 

Statistically significant observations of Group A
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It can be inferred that statistically significant increase in Hb (gm%) (*P*\<0.001), TRBC (×10^12^/l), PCV (%), and SGOT cannot be directly correlated with the *Drava Guna* concept. But as all these parameters can be included in *Pitta Varga*, it can be said that *Bhringaraja* has positive correlation with *Pitta*. Increase in these parameters can be taken as increase in *Agnimabhutatmaka* portion of *Pitta*. It is a hypothetical explanation which requires further logics to prove it. As there is no statistically significant increase or decrease in parameters like serum cholesterol, low density lipoprotein (LDL), and Total Leukocyte Count (TLC) which are considered as *Kapha Varga* parameters, it can be said that *Bhringaraja* has not that much effect on *Kapha Varga* parameters. The test drug did not cause abnormal deviation (out of normal physiological limit) in parameters but helped to maintain them within normal limits (e.g. statistically significant increase in SGOT was observed, but it was within normal range).

Overall effect of therapy in percentage {#sec2-15}
---------------------------------------

Moderate to marked (summation of moderate+marked) improvement was observed in more than 80% and 14.29% of patients in groups A and B, respectively, when data were presented in percentage improvement method \[[Table 17](#T17){ref-type="table"}\]. 80% and 14.29% values distinctly show the efficacy of *Bhringaraja* in contrast to placebo.

###### 

Overall effect of therapy in percentage
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Overall effect of therapy with Chi-square test {#sec2-18}
----------------------------------------------

Group A (*Bhringaraja* administered) showed statistically highly significant effects on chief complaints as compared to placebo \[[Table 18](#T18){ref-type="table"}\]. This indicates that though nonsignificant results were obtained when the symptoms were looked at separately, *Bhringaraja* showed increased efficacy when the overall effect was considered.

###### 

Total effect of therapy (Chi-square test) wise distribution of 22 patients
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Probable mode of action of *Bhringaraja* in *Amlapitta* {#sec2-19}
-------------------------------------------------------

In *Amlapitta*, *Drava Guna* of *Pitta* gets increased leading to pathogenesis. If *Drava Guna* increases, for reducing it one should use drugs which have opposite properties to that of *Drava Guna* (according to *Samanya-Vishesha Siddhanta*).\[[@ref7]\] *Bhringaraja*, the selected drug, has opposite properties (like *Ruksha--Ushna*)\[[@ref8]\] to that of *Drava Guna*, by means of which it is able to reduce increased *Drava Guna* and its actions. As per the classical view, *Ruksha Dravya* (like *Bhringaraja*) can reduce *Dravata*.\[[@ref9]\] *Ushna Virya Dravya* (like *Bhringaraja*) can reduce *Dravata* of *Grahanistha Sama Pitta*.\[[@ref10]\] *Bhringaraja* has both these properties, i.e. *Ruksha* and *Ushna Virya*. That is why *Bhringaraja* is capable of reducing *Drava Guna* of *Pitta* in *Amlapitta*. *Drava Guna* is a *Jalamahabhuta* property, while *Bhringaraja* is *Agnimahabhuta* dominant drug. Hence, *Bhringaraja* is supposed to decrease the *Drava Guna*, which has been verified clinically on *Drava Bahula Amlapitta* patients. The present research is helpful to study a different aspect of *Amlapitta* with emphasis on *Drava* property of *Pitta Dosha*. The data support the findings of previous research done at Tata Memorial Hospital, which suggest *Jeerna Amlapitta* as the predisposing disease factor responsible for Cancer of esophagus caused by consumption of excess *Amla* (sour), *Lavan* (salty), *Ushna* (hot), *Snigdha* (unctuous) dominant diet. These factors increase the *Drava* property of *Pitta* and may indeed lead to dreadful diseases.

Conclusion {#sec1-4}
==========

The above explanation proves that *Bhringaraja* has efficacy in treating the *Drava Bahula Amlapitta* in comparison to placebo. *Bhringaraja* can give moderate to marked improvement in *Drava Bahula Amlapitta* patients. Statistically significant results observed in Group A (*Bhringaraja*) specify that the applied concept of *Drava Guna* plays an important role in the pathogenesis of disease. Hence, *Bhringaraja* having *Drava* opposite properties, i.e. *Ruksha--Ushna*, can be a choice of remedy for the physician while treating diseases of *Pitta Drava Guna Vriddhi* like *Amlapitta*.
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